L&C BIO(290650) said on the 7th that it registered a domestic patent for an injectable tissue reconstruction technology using extracellular matrix (ECM) extracted from human tendons.
The patent is a technology that removes cells and fat from human tendon tissue, processes the ECM into micro-particles, and makes it injectable. It also secured conditions needed for actual products, including particle size, viscosity, and injection force.
L&C BIO plans to use this technology to develop products applicable to tendon and ligament areas such as the Achilles tendon and shoulder tendons. Following bone and cartilage, it aims to expand the "tissue-customized ECM platform" to tendons and ligaments.
Previously, the company developed and commercialized ECM "Re2O" to supplement skin tissue; "Mega DBM (demineralized bone matrix)" to reconstruct bone lost due to trauma or osteoporosis; ECM "MegaCarti" used for knee cartilage defects and osteoarthritis; and ECM "MegaNerve" to replace damaged peripheral nerves.
Lee Gi-won, head of the research and development division at L&C BIO, said, "It is meaningful to have secured the core technology to implement a material that leverages the unique ECM characteristics of human tendons in an actual injectable formulation," adding, "We will diversify the musculoskeletal ECM product lineup from bone and cartilage to tendons and ligaments, and expand the tissue-customized ECM platform to various tissues such as skin and nerves."